Collegium Pharmaceutical (COLL) Fundamentals 2026 — P/E 14.7x, Revenue Analysis | SniperIQ
Collegium Pharmaceutical (COLL) is a US-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of
4.91 on the NASDAQ. This SniperIQ fundamentals page covers Collegium Pharmaceutical's valuation (P/E 14.7x, P/B 3.6x), profitability (net margin 9.4%), revenue ($781M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Collegium Pharmaceutical's market cap?
Collegium Pharmaceutical (COLL) has a market capitalization of approximately
4.91 on the NASDAQ. Market cap moves with the live share price.What is Collegium Pharmaceutical's P/E ratio?
Collegium Pharmaceutical's trailing twelve-month P/E ratio is 14.7x, with a price-to-book (P/B) of 3.6x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Collegium Pharmaceutical?
Collegium Pharmaceutical runs a net profit margin of 9.4%, a gross margin of 60.7%, and an operating margin of 23.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Collegium Pharmaceutical generate?
Collegium Pharmaceutical reported revenue of $781M for fiscal year 2025, with net income of $63M and earnings per share (EPS) of 1.98. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Collegium Pharmaceutical pay a dividend?
Collegium Pharmaceutical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Collegium Pharmaceutical financially healthy?
Collegium Pharmaceutical carries a debt-to-equity ratio of 2.59x and a current ratio of 1.71x, with a market beta of 0.73. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Collegium Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Collegium Pharmaceutical (COLL) the key facts are: market cap
Track Collegium Pharmaceutical's full fundamentals live
Get Collegium Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.